A groundbreaking trial across 11 countries reveals a triple-action cancer jab can completely eradicate tumours in patients with advanced, treatment-resistant cancers.
The study spanned across 11 countries
May 31, 2026
05:58 pm
What's the storyA revolutionary cancer treatment, a triple-action jab called amivantamab, has shown unprecedented results in an international trial.
The study spanned across 11 countries and involved patients whose cancer had spread or recurred and failed to respond to other treatments.
Cancer jab can eradicate entire tumours in patients, trial shows
New Cancer Jab Eliminates Tumors in Patients as Trial Delivers Breakthrough Results - Novinite.com - Sofia News Agency
NHS cancer jab eradicates tumours
Doctors hail cancer injection that can destroy entire tumors
New cancer jab returns ‘unprecedented’ results in major clinical trial
Cancer jab 'eradicates whole tumours' in 15 patients - 7 key things to know
Cancer jabs destroy whole tumours in treatment-resistant cases, trial shows
Doctors report breakthrough as cancer jab reportedly eradicates tumours in international trial across 11 countries
Cancer trial shows promising results for treatment-resistant tumors
Tumori, «un vaccino può eliminarli»: il nuovo studio dai risultati «senza precedenti». Cos'è l'Amivantamab e quali sono gli effetti collaterali
Jab brought ‘unprecedentedly strong responses’ in patients whose disease had become resistant to chemotherapy and immunotherapy
A new experimental cancer treatment is generating significant excitement among oncologists after clinical trial results showed it…
The effectiveness of amivantamab is being evaluated in around 60 clinical trials worldwide.
Triple-action therapy drug amivantamab could be given as an injection to help treat recurrent or metastatic cancers
The results of the trial will be presented during the American Society of Clinical Oncology annual meeting in Chicago
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank…
